Vycor Medical (VYCO) 10-Q 15 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	12-May-14
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'VYCOR MEDICAL INC	'
Entity Central Index Key	'0001424768	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	10,703,494

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current Assets	'	'
Cash	$2,707,089	$31,303
Trade accounts receivable, net of allowance for doubtful accounts of $6,470 and $6,474	289,018	212,660
Inventory	228,371	206,926
Prepaid expenses and other current assets	238,039	208,063
Total Current Assets	3,462,517	658,952
Fixed assets, net	674,637	706,197
Intangible and Other assets:	'	'
Trademarks	251,157	251,157
Patents, net of accumulated amortization	412,718	444,095
Website, net of accumulated amortization	7,140	1,680
Security deposits	53,169	53,169
Total Intangible and Other assets	724,184	750,101
TOTAL ASSETS	4,861,338	2,115,250
Current Liabilities	'	'
Accounts payable	166,111	254,024
Accrued interest: Related Party	272,405	238,299
Accrued interest: Other	18,248	147,985
Accrued liabilities	325,244	1,776,867
Other current liabilities	88,804	61,576
Derivative liability - warrants	1,511,033	'
Notes payable: Related Party	'	2,373,556
Notes payable: Other	328,338	578,186
TOTAL CURRENT LIABILITIES	2,710,183	5,430,493
Notes payable long-term: Related Party	2,247,037	'
Notes payable long-term: Other	151,450	'
TOTAL LIABILITIES	5,108,670	5,430,493
STOCKHOLDERS' DEFICIENCY	'	'
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 1.0 and 16.2 issued and outstanding as at March 31, 2014 and December 31, 2013 respectively	'	1
Common Stock, $0.0001 par value, 25,000,000 shares authorized, 10,285,832 and 6,757,225 shares issued and outstanding at March 31, 2014 and December 31, 2013 respectively	1,028	675
Additional Paid-in Capital	17,617,736	13,762,689
Treasury Stock (103,334 shares of Common Stock as of March 31, 2014 and December 31, 2013 respectively, at cost)	-1,033	-1,033
Accumulated Deficit	-17,820,415	-17,032,405
Accumulated Other Comprehensive Income	-44,648	-45,170
Total Stockholders' Deficiency	-247,332	-3,315,243
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	$4,861,338	$2,115,250

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Balance Sheets [Abstract]	'	'
Allowance for doubtful accounts receivable	$6,470	$6,474
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	1	16.2
Preferred stock, shares outstanding	1	16.2
Common Stock, par value (in dollars per share)	$0.00	$0.00
Common Stock, shares authorized	25,000,000	25,000,000
Common Stock, shares issued	10,285,832	6,757,225
Common Stock, shares outstanding	10,285,832	6,757,225
Treasury Stock, shares	103,334	103,334

Consolidated_Statement_of_Oper

Consolidated Statement of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Statement of Operations [Abstract]	'	'
Revenue	$358,122	$231,674
Cost of Goods Sold	42,957	30,018
Gross Profit	315,165	201,656
Operating expenses:	'	'
Research and development	15,356	31,350
Depreciation and Amortization	94,096	86,269
General and administrative	1,198,252	683,658
Total Operating expenses	1,307,704	801,277
Operating loss	-992,539	-599,621
Other income (expense)	'	'
Interest expense: Related Party	-33,829	-28,967
Interest expense: Other	-14,294	-13,926
Change in fair value of warrants	253,284	'
Total Other income (expense)	205,161	-42,893
Net loss	-787,378	-642,514
Comprehensive Loss	'	'
Foreign Currency Translation Adjustment	-632	-20,158
Net Comprehensive Loss	($788,010)	($662,672)
Loss Per Share	'	'
Basic and diluted	($0.09)	($0.11)
Weighted Average Number of Shares Outstanding	8,995,082	5,947,998

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net comprehensive loss	($788,010)	($662,672)
Adjustments to reconcile net comprehensive loss to cash used in operating activities:	'	'
Amortization of intangible assets	36,906	30,186
Depreciation of fixed assets	60,337	62,951
Share based compensation expense	168,655	88,125
Change in fair value of warrants	-253,284	'
Changes in assets and liabilities:	'	'
Accounts receivable	-76,361	60,195
Inventory	-21,446	22,464
Prepaid expenses	-75,635	-1,144
Accounts payable	-80,833	26,987
Accrued interest: Related Party	33,829	28,969
Accrued interest: Other	-129,459	13,926
Accrued liabilities	-8,652	78,315
Other current liabilities	3,887	-12,048
Cash used in operating activities	-1,130,066	-263,746
Cash flows used in investing activities:	'	'
Purchase of fixed assets	-29,634	-10,063
Acquisition of subsidiary: deferred consideration paid	'	-89,945
Purchase of website	-5,628	'
Acquisition of patents	-5,361	-39,141
Cash used in investing activities	-40,623	-139,149
Cash flows from financing activities:	'	'
Proceeds from issuance of Common Stock, Offering	4,070,140	'
Net proceeds from issuance of Notes Payable: Related Party	'	334,000
Net proceeds from issuance of Notes Payable: Other	28,525	18,737
Repayment of Notes Payble: Related Party	-126,519	'
Repayment of Notes Payable: Other	-126,923	-12,111
Cash provided by financing activities	3,845,223	340,626
Effect of exchange rate changes on cash	1,252	18,372
Net increase (decrease) in cash	2,675,786	-43,897
Cash at beginning of period	31,303	59,821
Cash at end of period	2,707,089	15,924
Supplemental Disclosures of Cash Flow information:	'	'
Interest paid:	143,871	197
Acquisition of subsidiary: Deferred consideration paid	'	'
Acquisition of subsidiary: Deferred consideration paid	'	89,945
Acquisition of subsidiary, net of cash acquired, Net	'	$89,945

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Basis of Presentation and Formation and Business of the Company [Abstract]	'
BASIS OF PRESENTATION	'
	1.  BASIS OF PRESENTATION
	The consolidated financial statements of the Company present the financial position, results of operations, and cash flows of Vycor Medical, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive financial statements have been condensed or omitted pursuant to such rules and regulations. The consolidated balance sheet as of December 31, 2013 derives from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
	The condensed consolidated financial statements for the three months ended March 31, 2014 and 2013, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition and results of operations. The results of operations for the three months ended March 31, 2014 and 2013 are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Certain prior period amounts have been reclassified to conform to the current presentation.

Formation_and_Business_of_the_

Formation and Business of the Company	3 Months Ended
	Mar. 31, 2014
Basis of Presentation and Formation and Business of the Company [Abstract]	'
FORMATION AND BUSINESS OF THE COMPANY	'
	2.  FORMATION AND BUSINESS OF THE COMPANY
	Business Description
	Vycor Medical, LLC was formed on June 17, 2005 as a New York Limited Liability Company. The Company changed its name to Vycor Medical, Inc. and converted to a Delaware Corporation on August 14, 2007 and issued 107 shares of common stock in exchange for each of the 1,122 partnership units outstanding at date of conversion. The assets, liabilities and operations of the Company did not change pursuant to this reorganization, and the accompanying financial statements are presented as if the change occurred on the first day of the earliest period presented.  Accordingly, all references to number of shares prior to the date of conversion are based upon the common stock equivalent of the partnership units outstanding on such dates.
	The Company designs, develops and markets neurological medical devices and therapies through two operating divisions: Vycor Medical and NovaVision.  Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals; NovaVision focuses on neuro-stimulation therapies and diagnostic devices for the treatment and screening of vision field loss.

Significant_Accounting_Policie

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Significant Accounting Policies [Abstract]	'
SIGNIFICANT ACCOUNTING POLICIES	'
	3.   SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation
	The consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation.
	Recent Accounting Pronouncements
	From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.
	Warrant Derivative Liability
	The Company accounts for the 2,062,108 Series A Warrants and Placement Agent Warrants issued in connection with or as a result of the Offering (all as defined in Note 6) in accordance with the guidance contained in ASC 815-40-15-7D, whereby under that provision, because they have anti-dilution rights, they do not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classifies the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised or until the anti-dilution provisions contained within the warrant agreements expire, and is classified in the balance sheet as a current liability. Any change in fair value of the warrant liability is recognized in the Company’s statement of operations as other income (loss).
	Software Development Costs
	The authoritative accounting guidance requires software development costs to be capitalized upon completion of the preliminary project stage.  Accordingly, direct internal and external costs associated with the development of the features and functionality of the Company’s software, incurred during the application development stage, are capitalized and amortized using the straight-line method of the estimated life of five years once the software has been brought into service. Capitalized software development costs for the three months ended March 31, 2014 and 2013 were $29,633 and $0, respectively. During the period the Company’s VRT 7.0 program completed the preliminary project stage, following which there was a capitalization of $8,171 of software development costs. Additional costs of $21,463 were capitalized for the Company’s NeuroEyeCoach program prior to being brought into service in March 2014 with a total capitalized value of $119,106
	Net Loss Per Share
	Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt.  Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.
	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:
		March 31,	March 31,
		2014	2013
	Stock options outstanding	5,557	5,557
	Warrants to purchase common stock	5,002,217	1,749,874
	Debentures convertible into common stock	518,631	368,726
	Preferred shares convertible into common stock	14,815	663,719
	Total	5,541,220	2,787,876

Notes_Payable

Notes Payable	3 Months Ended
	Mar. 31, 2014
Notes Payable [Abstract]	'
NOTES PAYABLE	'
	4.   NOTES PAYABLE
	Related Party Notes Payable
	As of March 31, 2014 and December 31, 2013 Related Party Notes Payable consists of:
		31-Mar-14	31-Dec-13
	On December 29, 2009 and February 3, 2010, the Company issued convertible debentures in the amount of $371,362 and $70,000, respectively, payable to Fountainhead Capital Management (“Fountainhead”), the beneficial owner of more than 50% of the Company’s common stock. These debentures accrue interest at a rate of 6% per annum. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $1.88 per share, subject to adjustment, and does not require bifurcation. These debentures were originally due August 31, 2010 and the due date has been extended over time to January 2, 2017, subject to certain conditions.	441,362	441,362
	On March 31, 2010 and October 14, 2010, the Company issued convertible debentures payable to Fountainhead in the amount of $85,000 and $90,000, respectively. These debentures accrue interest at a rate of 6%. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $2.63 per share, subject to adjustment and does not require bifurcation. The debentures were originally due August 31, 2011, and the due date has been extended over time to January 2, 2017, subject to certain conditions.	175,000	175,000
	On October 26, 2010 and November 15, 2010, the Company issued debentures payable to Fountainhead in the amount of $77,500 and $322,500, respectively. These debentures accrue interest at a rate of 6% per annum. These debentures were originally due August 31, 2011 and the due date has been extended over time to January 2, 2017, subject to certain conditions.	400,000	400,000
	On November 15, 2010, the Company issued a convertible debenture in the amount of $350,000 payable to Peter Zachariou, a Director of the Company. This debenture accrues interest rate of 6% per annum. The Holder is entitled to convert all or any amount of the principal face amount of the debenture then outstanding into shares of common stock of the Company at the conversion price of $2.85 per share, subject to adjustment and does not require bifurcation. On December 20, 2010, the Company repaid $50,000 of this debenture and removed the convertible rights. The debentures were originally due December 31, 2012 and the due date has been extended over time to January 2, 2017, subject to certain conditions.	300,000	300,000
	In the period July to December 2012 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $300,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date has been extended over time to January 2, 2017, subject to certain conditions.	300,900	300,900
	In the period August to December 2012 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $115,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date has been extended over time to January 2, 2017, subject to certain conditions.	115,550	115,550
	In the period January to September 2013 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $325,744. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date has been extended over time to January 2, 2017, subject to certain conditions.	324,225	324,225
		-	91,519
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $91,519. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. These notes were repaid in January and February 2014.
		190,000	190,000
	In the period January to September 2013 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $210,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date has been extended over time to January 2, 2017, subject to certain conditions.
		-	20,000
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $20,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in February 2014
		-	15,000
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to David Cantor, in the aggregate amount of $15,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in 2014
	Total Related Party Notes Payable:	$2,247,037	$2,373,556
	Other Notes Payable
	As of March 31, 2014 and December 31, 2013 Other Notes Payable consists of:
		31-Mar-14	31-Dec-13
	On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011. In connection with the loan the Company also issued EuroAmerican warrants to purchase 400,000 shares of the Company’s common stock at an exercise price of $4.50 per share for a period of three (3) years. On June 25, 2011 the due date for this note was extended to September 25, 2011 and the Holder was granted the right to convert all or any amount of the principal face amount of the debenture then outstanding and accrued interest into shares of common stock of the Company an adjusted  conversion price of $1.80 per share, subject to adjustment and does not require bifurcation. The due date for this note has been extended over time to January 2, 2015, subject to certain conditions.	300,000	300,000
	In the period August to December 2012 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $98,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date for this note has been extended over time to January 2, 2017, subject to certain conditions.	98,550	98,550
	In September 2012 the Company issued short term, unsecured notes payable to Osbaldo Trading Limited in the amount of $42,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date for this note has been extended over time to January 2, 2017, subject to certain conditions.	42,900	42,900
	In the period June to September 2013 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $10,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date for this note has been extended over time to January 2, 2017, subject to certain conditions.	10,000	10,000
		-	3,000
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $3,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in February 2014.
	On October 22, 2013 the Company issued a term note for $100,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due November 30, 2013. This note was repaid in January 2014.	-	100,000
		28,338	23,736
	Insurance policy finance agreements. During the three months ended March 31, 2013 the Company received proceeds from Insurance policy finance agreement of $28,525 and made repayments of $23,923
	Total Other Notes Payable:	$479,788	$578,186
	The following is a schedule of future minimum loan repayments:
	,
	Twelve months ending March 31	Related Party	Other
	2014	-	328,338
	2015	-	-
	2016	-	-
	2017	2,247,037	151,450
		$2,247,037	$479,788
	The company assesses the value of the beneficial conversion feature of its convertible debt by determining the intrinsic value of such conversion, under ASC 470, at the time of issuance. At the time of issuance of each of the convertible debt instruments set out above, the fair value of the stock was either the same or less than the conversion price, and so there was no value attributable to any beneficial conversion feature.

Segment_Reporting_Geographical

Segment Reporting, Geographical Information	3 Months Ended
	Mar. 31, 2014
Segment Reporting, Geographical Information [Abstract]	'
SEGMENT REPORTING, GEOGRAPHICAL INFORMATION	'
	5.   SEGMENT REPORTING, GEOGRAPHICAL INFORMATION
	(a) Business segments
	The Company operates in two business segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neuro stimulation therapies and diagnostic devices for the treatment and screening of vision field loss and which includes Sight Science. Set out below are the revenues, gross profits and total assets for each segment.
	Table insert – table
		Three Months Ended March 31,
		2014	2013
	Revenue:
	Vycor Medical	$263,711	$130,665
	NovaVision	94,411	101,009
	Total Revenue	$358,122	$231,674
	Gross Profit:
	Vycor Medical	$233,409	$116,279
	NovaVision	81,756	85,377
	Total Gross Profit	$315,165	$201,656
		March 31,	December 31,
		2014	2013
	Total Assets:
	Vycor Medical	$3,562,302	$799,120
	NovaVision	1,299,036	1,316,130
	Total Assets	$4,861,338	$2,115,250
	(b) Geographic information
	The Company operates in two geographic segments, the United States and Europe. Set out below are the revenues, gross profits and total assets for each segment.
	Table insert – table
		Three Months Ended March 31,
		2014	2013
	Revenue:
	United States	$293,161	$156,785
	Europe	64,961	63,336
	Total Revenue	$358,122	$220,121
	Gross Profit:
	United States	$258,241	$156,188
	Europe	$56,924	45,468
	Total Gross Profit	$315,165	$201,656
		March 31,	December 31,
		2014	2013
	Total Assets:
	United States	$4,413,757	$1,604,142
	Europe	447,581	511,108
	Total Assets	$4,861,338	$2,115,250

Equity

Equity	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
EQUITY	'
	6.   EQUITY
	The Offering
	On January 2, January 31, February 28 and March 31, 2014, the Company completed four separate closings (the “Closings” of an offering (the “Offering”) of Units comprising shares of common stock (“Common Stock”) (collectively, the “Shares” and individually, a “Share”) and Series A and Series B Warrants (collectively, the “Warrants”) (collectively, the “Units”) to accredited investors (the “Investors”) in a private placement. The Closings comprised the sale of an aggregate of $4,070,140 in the Units), which were issued pursuant to four separate Securities Purchase Agreements between the Company and the Investors in each of the four Closings.  In the aggregate, the Company issued 2,261,214 shares of Common Stock, Series A Warrants to purchase an aggregate of 1,130,621 shares of Common Stock and Series B Warrants to purchase an aggregate of 1,130,621 shares of Common Stock.
	Each Unit was priced at $1.80 and comprised of one share of Common Stock, a Series A warrant (the “Series A Warrants”) and a series B warrant (the “Series B Warrants”). The Series A Warrants were detachable and were exercisable over a three-year term and were issued with respect to the purchase of a number of shares of Common Stock equal to 50% of the number of Shares purchased by such investor at an exercise price per share of $2.05.   The Series B Warrants were detachable and were exercisable over a three-year term and were issued with respect to the purchase of a number of shares of Common Stock equal to 50% of the number of Shares purchased by such investor at an exercise price per share of $3.08. The Warrants are subject to adjustment for stock splits, stock dividends or recapitalizations.
	Also on January 2, 2014, Fountainhead exchanged an aggregate of $1,426,542 of consulting fees owed to it by the Company for the Units issued in the Offering. In the aggregate, the Company issued to Fountainhead 792,523 shares of Common Stock, Series A Warrants to purchase an aggregate of 396,262 shares of Common Stock and Series B Warrants to purchase an aggregate of 396,262 shares of Common Stock.
	Based on the subscription terms applicable to the holders of the Company’s previously-issued Series C Convertible Preferred Stock, such holders were given the option of exchanging their investment in such unconverted Series C Convertible Preferred Stock and the related warrants into the securities which are the subject of the Offering, based on the amount of their investment in the Series C Convertible Preferred Stock and the related warrants.  On February 24, 2014, the holders of 15.15 shares of Series C Convertible Preferred Stock (representing an aggregate investment of $757,700) exchanged their Series C Convertible Preferred Stock and related warrants for an aggregate of 420,838 shares of Common Stock, Series A Warrants to purchase an aggregate of 210,419 shares of Common Stock and Series B Warrants to purchase an aggregate of 210,419 shares of Common Stock.
	Under the terms of the Placement Agent agreement with Garden State Securities, Inc. (“GSS”) (see Note 10), the Company issued an aggregate of 324,805 Placement Agent Warrants, on almost identical terms to the Series A Warrants.
	Subject to certain limitations, from the date each Investor enters into the Securities Purchase Agreement until the twelve-month anniversary of the Effective Date (as defined in the Securities Purchase Agreement), each Investor will receive additional shares of Company Common Stock for any such additional securities issued by the Company in a subsequent financing at an effective per share purchase price below $1.80; these rights are non-transferable The Series A Warrants and Placement Agent Warrants have anti-dilution protection during the same period for the issuance of Company Common Stock, or securities exercisable for or convertible into Company Common Stock, at an issuance price, exercise price or conversion price of less than the $2.05 exercise price of the Series A Warrants. Accordingly, 2,261,214 shares of Common Stock are subject to anti-dilution and are shown separately on the balance sheet; and an aggregate of 2,062,108 Series A Warrants and Placement Agent Warrants are subject to anti-dilution and are recorded as a derivative liability (see Note 2 and Note 8)
	Other Equity Transactions
	During January to March 2014, the Company issued 2,294 shares of Common Stock (valued at $5,000) to Steven Girgenti, 2,222 shares of Common Stock (valued at $5,000) to Oscar Bronsther and 2,222 shares of Common Stock (valued at $5,000) to Lowell Rush in consideration for services provided to the Board of Directors; and 710 shares of Common Stock (valued at $1,563) to Alvaro Pasual-Leone, 1,420 shares of Common Stock (valued at $3,125) to Josef Zihl and 694 shares of Common Stock (valued at $1,563) to each of Jason Barton and Jose Romano in respect of their roles as members of the NovaVision, Inc. Scientific Advisory Board.
	During January 2014, the Company issued 3,000 and 2,000 shares of Common Stock (valued at $5,400 and $3,600) to Del Mar Consulting Group, LLC and Alex Partners respectively under the terms of their advisory amendment agreements.
	On March 11, 2014 the Company entered into an Amendment Agreement with GSS. Under the Amendment Agreement, the Company agreed to issue 30,000 shares of Common Stock (valued at $66,000) on the date of the Amendment Agreement in respect of the period January to June 2014, rather than 7,500 shares per month under the original agreement.
	During March 2014, in accordance with the terms of an investor relations advisory agreement, the Company issued 2,500 shares of Common Stock (valued at $4,700) to J and M Group, LLC.
	On March 31 2014, in accordance with the terms the Consulting Agreement, the Company issued 6,276 shares of Common Stock (valued at $15,000) to Fountainhead.

ShareBased_Compensation

Share-Based Compensation	3 Months Ended
	Mar. 31, 2014
Share-Based Compensation [Abstract]	'
SHARE-BASED COMPENSATION	'
	7.   SHARE-BASED COMPENSATION
	Stock Option Plan
	The Company adopted the Vycor Medical, Inc Employee, Director, and Consultant Stock Plan (the “Plan”) as of February 13, 2008.  The Plan provides for both incentive stock options and nonqualified stock options to be granted to employees, officers, consultants, independent contractors, directors and affiliates of the Company.   The board of directors establishes the terms and conditions of all stock option grants, subject to the Plan and applicable provisions of the Internal Revenue Code.  Incentive stock options must be granted at an exercise price not less than the fair market value of the common stock on the grant date.  The options granted to participants owning more than 10% of the Company’s outstanding voting stock must be granted at an exercise price not less than 110% of the fair market value of the common stock on the grant date.  The options expire on the date determined by the board of directors, but may not extend mare than 10 years from the grant date, while incentive stock options granted to participants owning more than 10% of the Company’s outstanding voting stock expire five years from the grant date. The vesting period for employees is generally over three years.  The vesting Period for non-employees is determined based on the services being provided. The maximum number of shares of stock which may be delivered under the plan shall automatically increase by a number sufficient to cause the number of shares covered by the plan to equal 10% of the total number of shares of stock then outstanding on a fully diluted basis.
	Under ASC Topic 718, the Company estimates the fair value of option awards on the date of grant using an option pricing model. The grant date fair value is recognized over the option vesting period, the period during which an employee is required to provide service in exchange for the award. No compensation cost is recognized for equity instruments for which employees do not render the requisite service. Under these standards, compensation cost for employee cost for employee stock-based awards is based on the estimated grant-date fair value and recognized over the vesting period of the applicable award on a straight-line basis.  No employee stock options were granted for the three month periods ended March 31, 2014 and 2013.
	Initial grants of options to purchase 500,000 shares were issued under the Plan on February 13, 2008 to each of Kenneth T. Coviello, the Company’s then Chief Executive Officer and then Heather N. Vinas, the Company’s President at an exercise price of $0.135 per share.  The options vested 33-1/3% on each of the first, second, and third anniversary of the grant and expire February 12, 2018. Following Heather Vinas’ resignation as President of the Company in May 2010, 166,667 unvested options were cancelled. These options have been fully expensed.
	Stock appreciation rights may be granted either on a stand alone basis or in conjunction with all or part of any other stock options granted under the plan.  As of March 31, 2014 there were no awards of any stock appreciation rights.
	The Company from time to time issues common stock, stock options or common stock warrants to acquire services or goods from non-employees. Common stock, stock options and common stock warrants issued to other than employees or directors are recorded on the basis of their fair value, which is measured as of the “measurement date” using an option pricing model. The “measurement date” for options and warrants related to contracts that have substantial disincentives to non-performance is the date of the contract, and for all other contracts is the vesting date. Expense related to the options and warrants is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant.
	The details of the outstanding rights, options and warrants and value of such rights, options and warrants are as follows:
	STOCK WARRANTS:	Number of shares		Weighted average exercise price
				per share
	Outstanding at December 31, 2012	1,749,874		$3.03
	Granted	-		-
	Exercised	-341,941		1.49
	Cancelled or expired	-3,334		10.5
	Outstanding at December 31, 2013	1,404,599		$3.39
	Granted	3,810,579		2.52
	Exercised	-		-
	Cancelled or expired	-212,961		4.5
	Outstanding at March 31, 2014	5,002,217		$2.68
	STOCK OPTIONS:	Number of shares		Weighted average exercise price
				per share
	Outstanding at December 31, 2012	5,557		$20.25
	Granted	-		-
	Exercised	-		-
	Cancelled or expired	-		-
	Outstanding at December 31, 2013	5,557		$20.25
	Granted	-		-
	Exercised	-		-
	Cancelled or expired	-		-
	Outstanding at March 31, 2014	5,557		$20.25
	As of March 31, 2014, the weighted-average remaining contractual life of outstanding warrants and options is 2.35 and 3.88 years, respectively.
	Non-Employee Stock Compensation
	During the three months ended March 31, 2014, the Company issued an aggregate of 2,294, 2,222 and 2,222 shares of common stock, respectively, valued at $5,000 to each of Steven Girgenti, Oscar Bronsther and Lowell Rush for services rendered to the board of directors. For the three months ended March 31, 2014, a total of $15,000 was recognized as share-based compensation for the issuance of these shares.
	During three months ended March 31, 2014 the Company issued an aggregate of 710, 694 and 694 shares of common stock, respectively, valued at $1,563, to each of Alvaro Pascual-Leone, Jason Barton and Jose Romano and 1,420 shares of common stock valued at $3,125 to Josef Zihl for services rendered to the Scientific Advisory Board of NovaVision. For the three months ended March 31, 2014, an aggregate of $7,813 was recognized as share-based compensation for the issuance of these shares.
	In November 2013, the Company entered into three-month extension amendments to the existing agreements with Del Mar Consulting, Inc. and Alex Partners, LLC under which 33,000 and 27,000 shares of Company Common Stock respectively were issued, valued at $66,000 and $54,000 respectively. The value of these shares was amortized over the period of the agreement, and for the three months ended March 31, 2014 stock compensation of $78,620 was recognized as share-based compensation in connection with these agreements. Under the extension agreement, the Company has the option to pay all or part of the monthly fees in cash and for January 2014 3,000 shares valued at $5,400 were issued to Del Mar and 2,000 shares valued at $3,600 were issued to Alex Partners.
	On July 2, 2013, the Company entered into an advisory agreement, amended March 11, 2014 with Garden State Securities, Inc.(“GSS”) to provide certain financial advisory services to the Company. Under the terms of the advisory agreement, the Company issued 30,000 restricted shares of Company Common Stock to GSS in March 2014 valued at $66,000, which is being amortized over the six months from January 1, 2014, being the remaining term of the agreement. For the three months ended March 31, 2014 stock compensation of $33,000 was recognized as share-based compensation in connection with this agreement.
	On January 2, 2014 the Company issued warrants to Dr. Donald O’Rourke to purchase 7,000 shares of Vycor Common Stock at an exercise price of $3.08 per share, exercisable for a period of three years. The fair value of these warrants was estimated at $5,522 using Black-Scholes and the full value was recognized immediately.
	On January 2, 2014 the Company and Fountainhead amended their Consulting Agreement. Under the Amendment, 6,276 shares valued at $15,000 were issued to Fountainhead in respect of fees for the three months ended March 31, 2014.
	In March 2014, the Company entered into an investor relations advisory agreement with J and M Group, LLC, under which the Company issued 2,500 shares of Common Stock valued at $4,700, which was fully expensed in the three months ended March 31, 2014.
	Aggregate stock-based compensation expense charged to operations for stock and warrants granted to the above non-employees for the three months ended March 31, 2013 was $168,655. As of March 31, 2014, there was $33,000 of total unrecognized compensation costs related to warrant and stock awards and non-vested options.
	Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The stock options or warrants meet the criteria for equity treatment and the fair value of the stock options or warrants granted is estimated at the grant date and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant.  The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option pricing model on the basis of the fair value of the underlying common stock on the measurement date, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing share price. Expected volatility is based on the historical volatility of a peer group of publicly traded companies.
	The following assumptions were used in calculations of the Black-Scholes option pricing model for the three months ended March 31, 2014 and 2013:
		Three months ended March 31,
		2014	2013
	Risk-free interest rates	0.78%	-
	Expected life	3 years	-
	Expected dividends	0%	-
	Expected volatility	75%	-
	Vycor Common Stock fair value	$2.05	-

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
FAIR VALUE MEASUREMENTS	'
	8.   FAIR VALUE MEASUREMENTS
	The Company has adopted ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period. The adoption of ASC 820 did not have an impact on the Company’s financial position or results of operations.
	The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis (the 2,062,108 Series A Warrants and Placement Agent Warrants issued as part of the Units in connection with the Offering) as of March 31, 2014 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the liability, and includes situations where there is little, if any, market activity for the liability :
	Description	31-Mar-14		Level 1	Level 2	Level 3
	Warrant Liability	$1,511,033		$-	$-	$1,511,033
	The table below provides a reconciliation of the beginning and ending balances for the liabilities measured using fair significant unobservable inputs (Level 3):
	Balance at December 31, 2013	$-
	Issuance of Series A Warrants and Placement Agent Warrants as part of Offering Units on January 2, January 31, February 24, February 28 and March 31, 2014	1,764,317
	Change in fair value	-253,284
	Balance at March 31, 2014	$1,511, 033
	The fair value of the Series A Warrants and Placement Agent Warrants was determined using a Monte Carlo Simulation. This model requires the input of highly subjective assumptions, including the expected price volatility, which is based on the historical volatility of a peer group of publicly traded companies. Changes in the subjective input assumptions can materially affect the estimate of fair value of the warrants and the Company’s results of operations could be impacted.
	The following assumptions were used in calculations of the Monte Carlo Simulation model for the three months ended March 31, 2014 and 2013:
		Three months ended March 31,
		2014	2013
	Risk-free interest rates	0.68-0.93%	-
	Expected life	3 years	-
	Expected dividends	0%	-
	Expected volatility	71-83%	-
	Vycor Common Stock fair value	$1.88-2.39	-

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	9.   COMMITMENTS AND CONTINGENCIES
	Lease
	The Company leases approximately 10,000 sq. ft located at 6401 Congress Ave., Suite 140, Boca Raton, FL 33487 from Catexor Limited Partnership for a gross rent of $14,260 plus sales tax per month.  The term of the lease is 5 years and 6 months terminating July, 2017. The Company’s subsidiaries in Germany and the UK occupy properties on short term lease agreements. Rent expense for the three months ended March 31, 2014 and 2013 were $50,178 and $48,553 respectively.
	Potential German tax liability
	In June 2012 the Company's German subsidiary received a preliminary assessment for Magdeburg City trade tax of approximately €75,000 (approximately $94,000). This assessment is for the 2010 fiscal year and relates to the Company's acquisition of the assets of the former NovaVision, Inc. An initial assessment for corporate tax for the same period has been preliminarily reduced to zero. The Company has not accepted this trade tax assessment and is in discussion with the relevant tax authorities with a view to its reduction. The tax authorities have agreed to suspend the assessment pending the outcome of certain court hearings, and the Company has agreed to make limited monthly payments on account. To the extent that this assessment, a higher or a reduced amount, is ultimately confirmed by the tax authorities, the Company believes it has a very strong claim against certain professional advisors which would offset the liability in full. Accordingly, the Company has made no provision for this liability for the three months ending March 31, 2014, other than recording the monthly payments as an expense.
	Potential Patent Infringement
	The Company was made aware in 2012 that a competitor had been granted a patent for related technology, and appeared to be entering the market with products that infringe the Company’s own issued patent. Following investigation, the Company has taken steps to initiate an invalidation of the competitor’s patent and enforce its patent rights; in March 2014 the Ptent Re-examination Board issued an Examination Decision invalidating all the claims of the competitor’s patent. The competitor has the right of appeal but the Company will contest any such appeal. The Company has also been made aware that a second competitor has filed a patent application for related technology and also may be producing a product that potentially infringes the Company’s patent, and is in the early stages of evaluation and has yet to determine what, if any actions to take in this instance, however as a general rule the Company intends to take all necessary action to protect its patent portfolio. As with all patent infringement actions, there is some risk that the accused infringer will not be found to infringe the claims, and an additional risk that the accused infringer will successfully challenge the validity of the asserted claims.

Consulting_and_Other_Agreement

Consulting and Other Agreements	3 Months Ended
	Mar. 31, 2014
Consulting and Other Agreements [Abstract]	'
CONSULTING AND OTHER AGREEMENTS	'
	10. CONSULTING AND OTHER AGREEMENTS
	The Company has entered into no new consulting or other agreements during the three months ended March 31, 2014, other than amendments to existing agreements outlined below. The following agreements remained in force during the period:
	Consulting Agreement with Fountainhead
	Effective as of January 2, 2014, the Company and Fountainhead amended their Consulting Agreement to extend the term of the Consulting Agreement to January 2, 2015.  As of January 2014, the monthly retainer payable to Fountainhead was reduced to $10,000 per month, payable $5,000 in cash and the remainder payable in Company Common Stock at the end of each quarter until the occurrence of specified milestones.
	Consulting Agreement with Del Mar Consulting Group, Inc and Alex Partners, LLC.
	In November 2013, the Company entered into three-month extension amendments to the existing agreements with Del Mar Consulting, Inc. and Alex Partners, LLC under which 33,000 and 27,000 shares of Company Common Stock respectively were issued, valued at $66,000 and $54,000 respectively. .
	Garden State Securites, Inc. (“GSS”) Advisory and Placement Agent Agreements
	On July 2, 2013, the Company entered into two agreements with GSS one to provide certain financial advisory services to the Company (“Advisory Agreement”) and the other to act as placement agent for the Company (“Placement Agent Agreement”).
	Under the terms of the Advisory Agreement, GSS is engaged on a non-exclusive basis to provide financial advisory services to the Company for at least ninety (90) days and thereafter until either party terminates the arrangement.  Under the terms of the Advisory Agreement, as amended on March 14, 2014, the Company will issue 45,000 restricted shares of Company Common Stock to the broker-dealer, 15,000 of which are issuable on the date of the execution of the Agreement and 30,000 additional shares to be issued on March 11, 2014.  The Agreement also calls for the Company to reimburse certain out-of-pocket expenses.
	Under the terms of the Placement Agent Agreement, the Company engaged GSS as its exclusive placement agent until the later of (i) 90 days from the date of execution of the Agreement or (ii) the end of the offering period of any securities financing undertaken by the Company in connection with the Placement Agent Agreement. Normal placement agents fees and expense reimbursement will be payable. Any offering will be undertaken on a “best efforts” basis and the proceeds would be used for working capital and general corporate purposes

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	11.  RELATED PARTY TRANSACTIONS
	Under the terms of the Offering, there were certain agreements with Related Parties:
	(a) Debt Amendment and Repayment.   Fountainhead and Peter Zachariou agreed to extend the maturity of all of the Company’s debt obligations due to them due to as of August 9, 2013 (aggregating $2,247,037) to January 2, 2017, subject to the earlier repayment of such debt upon the occurrence of certain specified conditions.  Fountainhead and Peter Zachariou further released all security interests associated with any of the obligations and agreed to forebear declaring any event of default under the obligations for a period of 24 months following the date of the Initial Closing. During January and February 2014, also under the terms of the Offering, debt obligations arising since August 9, 2013 were repaid as follows: Fountainhead - $91,519; Peter Zachariou - $20,000; David Cantor - $15,000.
	(b)
	Employment of Chief Executive Officer and Employment Agreements.  Effective as of January 2, 2014, our board of directors appointed Peter C. Zachariou, our Executive Vice President, to the additional role as the Company’s Chief Executive Officer. Also effective as of the January 2, 2014 the Company entered into separate, but largely identical Employment Agreements with Mr. Zachariou, Adrian Liddell and David Cantor. Mr. Zachariou’s Employment Agreement commences on the Effective Date and terminates six months following the appointment of a successor Chief Executive Officer; Mr. Liddell’s Employment Agreement commences on the Effective Date and terminates upon the appointment of a successor Chief Financial Officer; and Mr. Cantor’s Employment Agreement commences on the Effective Date and terminates upon the appointment of a successor. The aforementioned Employment Agreements provide for annual compensation of $110,000, payment of which is deferred for 12 months from the Effective Date and is subject to the achievement of certain enumerated milestone conditions. Each of these Employment Agreements supersede any prior employment agreements or arrangements between the respective parties.
	(c)
	Amendment to Consulting Agreement. Effective as of January 2, 2014, the Company and Fountainhead amended their Consulting Agreement to extend the term of the Consulting Agreement to to January 2, 2015.  As of January 2014, the monthly retainer payable to Fountainhead was reduced to $10,000 per month, payable $5,000 in cash and the remainder payable in Company Common Stock at the end of each quarter until the occurrence of specified milestones.
	(d)
	Conversion Agreement. Effective as of January 2, 2014, the Company and Fountainhead entered into a Conversion Agreement whereby Fountainhead agreed to convert all amounts accrued as of the date of the Initial Closing into an investment in that amount in the Offering.  Pursuant to the terms of this agreement, Fountainhead converted $1,426,542 of accrued consulting fees into the Units.
	On March 31 2014, in accordance with the terms the Consulting Agreement, the Company issued 6,276 shares of Common Stock (valued at $15,000) to Fountainhead.
	There were no other related party transactions during the three months ended March 31, 2014 other than the payment or accrual of fees under the Fountainhead Consulting agreement described in Note 11 of the financial statements.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	12. SUBSEQUENT EVENTS
	The Company evaluated subsequent events through the date the financial statements were issued and filed with this Form 10Q:
	Share Issuance
	During April to May 2014, the Company issued 2,222 shares of Common Stock (valued at $5,000) to Steven Girgenti, in consideration for services provided to the Board of Directors; and 727 and 1,453 shares of Common Stock respectively (valued at $1,563 and $3,125 respectively) to Alvaro Pascual-Leone and Josef Zihl in respect of their roles as members of the NovaVision, Inc. Scientific Advisory Board.
	On April 25, 2014, the Company completed the sale of an additional $929,860 in Units in a final close of the Offering, which were issued pursuant to a Securities Purchase Agreement between the Company and the Investors. In the aggregate, the Company issued 516,594 shares of Common Stock, Series A Warrants to purchase an aggregate of 258,298 shares of Common Stock and Series B Warrants to purchase an aggregate of 258,298 shares of Common Stock.
	Amendment to Offering Agreements and removal of anti-dilution
	During April and May 2014, the Company requested waivers of certain anti-dilution provisions of the Stock Purchase Agreement and Series A Warrant Agreements (“Waivers”) which were executed with investors in the Company’s $5,000,000 private placement offering which was completed on April 25, 2014. Under the terms of the Waivers, the investors agreed to waive their anti-dilution rights (which arose in the event the Company sold securities at a price below $2.05 within one year of the date that the initial Registration Statement has been declared effective by the SEC) in consideration of the Company’s agreement not to sell any securities at a price below $2.05 within such one-year period. The Waivers become effective as to all the Common Stock issued in the offering once the Company receives the agreement of the holders of eighty percent (80%) of the Common Stock issued in the offering and the holders of eighty percent (80%) of the Common Stock issued in each closing. As of May 14, 2014, the Company had received waivers from the holders of 93.9 percent of the shares issued in the offering, and over 80 percent for each closing, and so the Waivers have been declared effective on 100 percent of the Common Stock issued in the Offering. The Company is continuing to seek Waivers from the remaining investors for their Common Stock and Series A Warrants. Waivers have also been received in respect of the Placement Agent Warrants and the Series A Warrants held by Fountainhead.
	As stated in Note 2 (Warrant Derivative Liability) and Note 8, because the Warrants carry certain anti-dilution protection for the holders, the Company has recorded the Series A Warrants and Placement Agent Warrants as a liability, in accordance with the guidance contained in ASC 815-40-15-7D. Following the declaration of effectiveness of the Waivers, the Company will no longer be required to record any derivative liability on account of the Series A Warrants and Placement Agent warrants, with respect of the actual number of Warrants for which the Waivers have been executed.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Significant Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.
Warrant Derivative Liability	'
	Warrant Derivative Liability
	The Company accounts for the 2,062,108 Series A Warrants and Placement Agent Warrants issued in connection with or as a result of the Offering (all as defined in Note 6) in accordance with the guidance contained in ASC 815-40-15-7D, whereby under that provision, because they have anti-dilution rights, they do not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classifies the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised or until the anti-dilution provisions contained within the warrant agreements expire, and is classified in the balance sheet as a current liability. Any change in fair value of the warrant liability is recognized in the Company’s statement of operations as other income (loss).
Software Development Costs	'
	Software Development Costs
	The authoritative accounting guidance requires software development costs to be capitalized upon completion of the preliminary project stage.  Accordingly, direct internal and external costs associated with the development of the features and functionality of the Company’s software, incurred during the application development stage, are capitalized and amortized using the straight-line method of the estimated life of five years once the software has been brought into service. Capitalized software development costs for the three months ended March 31, 2014 and 2013 were $29,633 and $0, respectively. During the period the Company’s VRT 7.0 program completed the preliminary project stage, following which there was a capitalization of $8,171 of software development costs. Additional costs of $21,463 were capitalized for the Company’s NeuroEyeCoach program prior to being brought into service in March 2014 with a total capitalized value of $119,106
Net Loss Per Share	'
	Net Loss Per Share
	Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt.  Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.
	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:
		March 31,	March 31,
		2014	2013
	Stock options outstanding	5,557	5,557
	Warrants to purchase common stock	5,002,217	1,749,874
	Debentures convertible into common stock	518,631	368,726
	Preferred shares convertible into common stock	14,815	663,719
	Total	5,541,220	2,787,876

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2014
Significant Accounting Policies [Abstract]	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'
		March 31,	March 31,
		2014	2013
	Stock options outstanding	5,557	5,557
	Warrants to purchase common stock	5,002,217	1,749,874
	Debentures convertible into common stock	518,631	368,726
	Preferred shares convertible into common stock	14,815	663,719
	Total	5,541,220	2,787,876

Notes_Payable_Tables

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2014
Notes Payable [Abstract]	'
Components of notes payable	'
		31-Mar-14	31-Dec-13
	On December 29, 2009 and February 3, 2010, the Company issued convertible debentures in the amount of $371,362 and $70,000, respectively, payable to Fountainhead Capital Management (“Fountainhead”), the beneficial owner of more than 50% of the Company’s common stock. These debentures accrue interest at a rate of 6% per annum. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $1.88 per share, subject to adjustment, and does not require bifurcation. These debentures were originally due August 31, 2010 and the due date has been extended over time to January 2, 2017, subject to certain conditions.	441,362	441,362
	On March 31, 2010 and October 14, 2010, the Company issued convertible debentures payable to Fountainhead in the amount of $85,000 and $90,000, respectively. These debentures accrue interest at a rate of 6%. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $2.63 per share, subject to adjustment and does not require bifurcation. The debentures were originally due August 31, 2011, and the due date has been extended over time to January 2, 2017, subject to certain conditions.	175,000	175,000
	On October 26, 2010 and November 15, 2010, the Company issued debentures payable to Fountainhead in the amount of $77,500 and $322,500, respectively. These debentures accrue interest at a rate of 6% per annum. These debentures were originally due August 31, 2011 and the due date has been extended over time to January 2, 2017, subject to certain conditions.	400,000	400,000
	On November 15, 2010, the Company issued a convertible debenture in the amount of $350,000 payable to Peter Zachariou, a Director of the Company. This debenture accrues interest rate of 6% per annum. The Holder is entitled to convert all or any amount of the principal face amount of the debenture then outstanding into shares of common stock of the Company at the conversion price of $2.85 per share, subject to adjustment and does not require bifurcation. On December 20, 2010, the Company repaid $50,000 of this debenture and removed the convertible rights. The debentures were originally due December 31, 2012 and the due date has been extended over time to January 2, 2017, subject to certain conditions.	300,000	300,000
	In the period July to December 2012 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $300,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date has been extended over time to January 2, 2017, subject to certain conditions.	300,900	300,900
	In the period August to December 2012 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $115,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date has been extended over time to January 2, 2017, subject to certain conditions.	115,550	115,550
	In the period January to September 2013 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $325,744. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date has been extended over time to January 2, 2017, subject to certain conditions.	324,225	324,225
		-	91,519
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $91,519. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. These notes were repaid in January and February 2014.
		190,000	190,000
	In the period January to September 2013 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $210,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date has been extended over time to January 2, 2017, subject to certain conditions.
		-	20,000
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $20,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in February 2014
		-	15,000
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to David Cantor, in the aggregate amount of $15,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in 2014
	Total Related Party Notes Payable:	$2,247,037	$2,373,556
		31-Mar-14	31-Dec-13
	On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011. In connection with the loan the Company also issued EuroAmerican warrants to purchase 400,000 shares of the Company’s common stock at an exercise price of $4.50 per share for a period of three (3) years. On June 25, 2011 the due date for this note was extended to September 25, 2011 and the Holder was granted the right to convert all or any amount of the principal face amount of the debenture then outstanding and accrued interest into shares of common stock of the Company an adjusted  conversion price of $1.80 per share, subject to adjustment and does not require bifurcation. The due date for this note has been extended over time to January 2, 2015, subject to certain conditions.	300,000	300,000
	In the period August to December 2012 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $98,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date for this note has been extended over time to January 2, 2017, subject to certain conditions.	98,550	98,550
	In September 2012 the Company issued short term, unsecured notes payable to Osbaldo Trading Limited in the amount of $42,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date for this note has been extended over time to January 2, 2017, subject to certain conditions.	42,900	42,900
	In the period June to September 2013 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $10,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date for this note has been extended over time to January 2, 2017, subject to certain conditions.	10,000	10,000
		-	3,000
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $3,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in February 2014.
	On October 22, 2013 the Company issued a term note for $100,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due November 30, 2013. This note was repaid in January 2014.	-	100,000
		28,338	23,736
	Insurance policy finance agreements. During the three months ended March 31, 2013 the Company received proceeds from Insurance policy finance agreement of $28,525 and made repayments of $23,923
	Total Other Notes Payable:	$479,788	$578,186
Schedule of future minimum loan repayments	'
	Twelve months ending March 31	Related Party	Other
	2014	-	328,338
	2015	-	-
	2016	-	-
	2017	2,247,037	151,450
		$2,247,037	$479,788

Segment_Reporting_Geographical1

Segment Reporting, Geographical Information (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting, Geographical Information [Abstract]	'
Business segments information	'
		Three Months Ended March 31,
		2014	2013
	Revenue:
	Vycor Medical	$263,711	$130,665
	NovaVision	94,411	101,009
	Total Revenue	$358,122	$231,674
	Gross Profit:
	Vycor Medical	$233,409	$116,279
	NovaVision	81,756	85,377
	Total Gross Profit	$315,165	$201,656
		March 31,	December 31,
		2014	2013
	Total Assets:
	Vycor Medical	$3,562,302	$799,120
	NovaVision	1,299,036	1,316,130
	Total Assets	$4,861,338	$2,115,250
Summary of geographic information	'
		Three Months Ended March 31,
		2014	2013
	Revenue:
	United States	$293,161	$156,785
	Europe	64,961	63,336
	Total Revenue	$358,122	$220,121
	Gross Profit:
	United States	$258,241	$156,188
	Europe	$56,924	45,468
	Total Gross Profit	$315,165	$201,656
		March 31,	December 31,
		2014	2013
	Total Assets:
	United States	$4,413,757	$1,604,142
	Europe	447,581	511,108
	Total Assets	$4,861,338	$2,115,250

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2014
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]	'
Shedule of the outstanding rights, options and warrants and value of such rights, options and warrants	'
	STOCK WARRANTS:	Number of shares		Weighted average exercise price
				per share
	Outstanding at December 31, 2012	1,749,874		$3.03
	Granted	-		-
	Exercised	-341,941		1.49
	Cancelled or expired	-3,334		10.5
	Outstanding at December 31, 2013	1,404,599		$3.39
	Granted	3,810,579		2.52
	Exercised	-		-
	Cancelled or expired	-212,961		4.5
	Outstanding at March 31, 2014	5,002,217		$2.68
	STOCK OPTIONS:	Number of shares		Weighted average exercise price
				per share
	Outstanding at December 31, 2012	5,557		$20.25
	Granted	-		-
	Exercised	-		-
	Cancelled or expired	-		-
	Outstanding at December 31, 2013	5,557		$20.25
	Granted	-		-
	Exercised	-		-
	Cancelled or expired	-		-
	Outstanding at March 31, 2014	5,557		$20.25
Assumptions used in calculations of the Black-Scholes option pricing model for options and warrants	'
		Three months ended March 31,
		2014	2013
	Risk-free interest rates	0.68-0.93%	-
	Expected life	3 years	-
	Expected dividends	0%	-
	Expected volatility	71-83%	-
	Vycor Common Stock fair value	$1.88-2.39	-
Stock options [Member]	'
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]	'
Assumptions used in calculations of the Black-Scholes option pricing model for options and warrants	'
		Three months ended March 31,
		2014	2013
	Risk-free interest rates	0.78%	-
	Expected life	3 years	-
	Expected dividends	0%	-
	Expected volatility	75%	-
	Vycor Common Stock fair value	$2.05	-

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Schedule liabilities measured at fair value on a recurring basis	'
	Description	31-Mar-14		Level 1	Level 2	Level 3
	Warrant Liability	$1,511,033		$-	$-	$1,511,033
Schedule of liabilities measured using fair significant unobservable inputs (Level 3)	'
	Balance at December 31, 2013	$-
	Issuance of Series A Warrants and Placement Agent Warrants as part of Offering Units on January 2, January 31, February 24, February 28 and March 31, 2014	1,764,317
	Change in fair value	-253,284
	Balance at March 31, 2014	$1,511, 033
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		Three months ended March 31,
		2014	2013
	Risk-free interest rates	0.68-0.93%	-
	Expected life	3 years	-
	Expected dividends	0%	-
	Expected volatility	71-83%	-
	Vycor Common Stock fair value	$1.88-2.39	-

Formation_and_Business_of_the_1

Formation and Business of the Company (Details)	0 Months Ended	3 Months Ended
	Aug. 14, 2007	Mar. 31, 2014
	Unit	Operation
Formation and Business of the Company (Textual)	'	'
Common stock issued in exchange for partnership units	107	'
Number of partnership units outstanding	1,122	'
Number of operation divisions	'	2

Significant_Accounting_Policie3

Significant Accounting Policies (Details Textual) (USD $)	3 Months Ended		3 Months Ended	1 Months Ended	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Feb. 24, 2014	Mar. 31, 2014
			Series A Warrants [Member]	Series A Warrants [Member]	Series A Warrants [Member]
				Placement Agent Agreement [Member]	Placement Agent Agreement [Member]
Significant Accounting Policies (Textual)	'	'	'	'	'
Software development costs	$8,171	'	'	'	'
Capitalized software development cost	29,633	0	'	'	'
Capitalized software development cost additions	21,463	'	'	'	'
Total capitalized value	$119,106	'	'	'	'
Shares issued during period	'	'	1,130,621	324,805	2,062,108

Going_Concern_Details

Going Concern (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Going Concern (Textual)	'	'	'	'
Net loss	($788,010)	($662,672)	'	'
Stockholders' deficit	-247,332	'	-3,315,243	'
Cash and cash equivalents	$2,707,089	$15,924	$31,303	$59,821

Significant_Accounting_Policie4

Significant Accounting Policies (Details)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	5,541,220	2,787,876
Stock options outstanding [Member]	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	5,557	5,557
Warrants to purchase common stock [Member]	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	5,002,217	1,749,874
Debentures convertible into common stock [Member]	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	518,631	368,726
Preferred shares convertible into common stock [Member]	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	14,815	663,719

Notes_Payable_Details

Notes Payable (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Components of notes payable	'	'
Total Related Party Notes Payable:	$2,247,037	'
Convertible debentures issued on December 29, 2009 and February 3, 2010 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	441,362	441,362
Convertible debentures issued on March 31, 2010 and October 14, 2010 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	175,000	175,000
Debentures payable issued on October 26, 2010 and November 15, 2010 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	400,000	400,000
Convertible debenture issued on November 15, 2010 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	300,000	300,000
Short term, unsecured notes payable issued on July to December 2012 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	300,900	300,900
Short term, unsecured notes payable issued on August to December 2012 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	115,550	115,550
Short term, unsecured notes payable issued on January to September 2013 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	324,225	324,225
Short term, unsecured notes payable issued on August 9 to December 2013 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	91,519
Short term, unsecured notes payable issued on January to September 2013 [Member] 1	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	190,000	190,000
Short term, unsecured notes payable issued on August 9 to December 2013 [Member] 1	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	20,000
Short term, unsecured notes payable issued on August 9 to December 2013 [Member] 2	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	15,000
Term notes issued on March 25, 2011[Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	300,000	300,000
Short term, unsecured notes payable issued to Craig Kirsch on August to December 2012 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	98,550	98,550
Short term, unsecured notes payable issued September 2012 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	42,900	42,900
Short term, unsecured notes payable issued to Craig Kirsch on June to September 2013 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	10,000	10,000
Short term, unsecured notes payable issued to Craig Kirsch on August 9 to December 2013 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	3,000
Term notes issued on October 22, 2013 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	100,000
Unsecured loans issued in August 9 to December 2013 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	'
Insurance policy finance agreements [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	28,338	23,736
Other Notes Payable [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	$479,778	$578,186

Notes_Payable_Details_1

Notes Payable (Details 1) (USD $)	Mar. 31, 2014
Related Party	'
Extinguishment of Debt [Line Items]	'
2014	'
2015	'
2016	'
2017	2,247,037
Total	2,247,037
Other	'
Extinguishment of Debt [Line Items]	'
2014	328,338
2015	'
2016	'
2017	151,450
Total	$479,788

Notes_Payable_Details_Textual

Notes Payable (Details Textual) (USD $)

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

Feb. 03, 2010

Dec. 29, 2009

Oct. 14, 2010

Mar. 31, 2010

Nov. 15, 2010

Oct. 26, 2010

Nov. 15, 2010

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 25, 2011

Mar. 31, 2014

Sep. 30, 2012

Mar. 31, 2014

Mar. 31, 2014

Oct. 22, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Convertible debentures issued on December 29, 2009 and February 3, 2010 [Member]

Convertible debentures issued on December 29, 2009 and February 3, 2010 [Member]

Convertible debentures issued on March 31, 2010 and October 14, 2010 [Member]

Convertible debentures issued on March 31, 2010 and October 14, 2010 [Member]

Debentures payable issued on October 26, 2010 and November 15, 2010 [Member]

Debentures payable issued on October 26, 2010 and November 15, 2010 [Member]

Convertible debenture issued on November 15, 2010 [Member]

Short term, unsecured notes payable issued on July to December 2012 [Member]

Short term, unsecured notes payable issued on January to September 2013 [Member]

Short term, unsecured notes payable issued on January to September 2013 [Member] 1

Term notes issued on March 25, 2011[Member]

Short term issued in August to December 2012 [Member]

Short term, unsecured notes payable issued September 2012 [Member]

Insurance policy finance agreements [Member]

Unsecured loans issued in August 9 to December 2013 [Member]

Term notes issued on October 22, 2013 [Member]

Short term, unsecured notes payable issued on August 9 to December 2013 [Member] 1

Short term, unsecured notes payable issued on August 9 to December 2013 [Member] 2

Short term, unsecured notes payable issued to Craig Kirsch on August to December 2012 [Member]

Short term, unsecured notes payable issued to Craig Kirsch on August 9 to December 2013 [Member]

Short term, unsecured notes payable issued to Craig Kirsch on June to September 2013 [Member]

Notes Payable (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of convertible debentures

$70,000

$371,362

$90,000

$85,000

$322,500

$77,500

$350,000

$300,900

$325,744

$210,000

'

$115,500

$42,900

$28,525

$91,519

$100,000

$20,000

$15,000

$98,550

$3,000

$10,000

Term notes payables

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

Percentage of company's common stock hold by beneficial owner

50.00%

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate on debentures

6.00%

6.00%

6.00%

6.00%

6.00%

6.00%

6.00%

6.00%

6.00%

6.00%

'

6.00%

6.00%

'

6.00%

16.00%

6.00%

6.00%

6.00%

6.00%

6.00%

Conversion price

$1.88

$1.88

$2.63

$2.63

'

'

$2.85

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayment of convertible debt

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate on term notes

'

'

'

'

'

'

'

'

'

'

16.00%

'

'

'

'

'

'

'

'

'

'

Number of common stock purchased by issuance of warrants

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants

'

'

'

'

'

'

'

'

'

'

$1.80

'

'

'

'

'

'

'

'

'

'

Period of warrants

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

Debt instrument, maturity date, description

'

'

'

'

'

'

'

'

'Due on demand or one year after the issue date

'Due on demand or one year after the issue date

'

'

'Due on demand or one year after the issue date

'

'Due on demand or one year after the issue date

'

'Due on demand or one year after the issue date

'Due on demand or one year after the issue date

'Due on demand or one year after the issue date

'Due on demand or one year after the issue date

'Due on demand or one year after the issue date

Debt instruments, original maturity date

31-Aug-10

31-Aug-10

31-Aug-11

31-Aug-11

31-Aug-11

31-Aug-11

31-Dec-12

'

'

'

25-Jun-11

'

'

'

'

30-Nov-13

'

'

'

'

'

Debt instruments, extended maturity date description

'Due date has been extended over time to January 2, 2017

'Due date has been extended over time to January 2, 2017

'Due date has been extended over time to January 2, 2017

'Due date has been extended over time to January 2, 2017

'Due date has been extended over time to January 2, 2017

'Due date has been extended over time to January 2, 2017

'Due date has been extended over time to January 2, 2017

'Due date has been extended over time to January 2, 2017,

'Due date has been extended over time to January 2, 2017

'Due date has been extended over time to January 2, 2017

'The due date for this note has been extended over time to January 2, 2015,

'due date has been extended over time to January 2, 2017

'Due date for this note has been extended over time to January 2, 2017

'

'

'

'

'

'The due date for this note has been extended over time to January 2, 2017,

'

'The due date for this note has been extended over time to January 2, 2017

Debt notes repaid description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'These notes were repaid in January and February 2014.

'This note was repaid in January 2014.

'This note was repaid in February 2014.

'This note was repaid in 2014.

'

'This note was repaid in February 2014.

'

Repayments of insurance policy

'

'

'

'

'

'

'

'

'

'

'

'

'

$23,923

'

'

'

'

'

'

'

Segment_Reporting_Geographical2

Segment Reporting, Geographical Information (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Revenue:	'	'	'
Total Revenue	$358,122	$231,674	'
Gross Profit:	'	'	'
Total Gross Profit	315,165	201,656	'
Total Assets:	'	'	'
Total Assets	4,861,338	'	2,115,250
Vycor Medical [Member]	'	'	'
Revenue:	'	'	'
Total Revenue	263,711	130,665	'
Gross Profit:	'	'	'
Total Gross Profit	233,409	116,279	'
Total Assets:	'	'	'
Total Assets	3,562,302	'	799,120
NovaVision [Member]	'	'	'
Revenue:	'	'	'
Total Revenue	94,411	101,009	'
Gross Profit:	'	'	'
Total Gross Profit	81,756	85,377	'
Total Assets:	'	'	'
Total Assets	$1,299,036	'	$1,316,130

Segment_Reporting_Geographical3

Segment Reporting, Geographical Information (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Revenue:	'	'	'
Total Revenue	$358,122	$231,674	'
Gross Profit:	'	'	'
Total Gross Profit	315,165	201,656	'
Total Assets:	'	'	'
Total Assets	4,861,338	'	2,115,250
United States [Member]	'	'	'
Revenue:	'	'	'
Total Revenue	293,161	156,785	'
Gross Profit:	'	'	'
Total Gross Profit	258,241	156,188	'
Total Assets:	'	'	'
Total Assets	4,413,757	'	1,604,142
Europe [Member]	'	'	'
Revenue:	'	'	'
Total Revenue	64,961	63,336	'
Gross Profit:	'	'	'
Total Gross Profit	56,924	45,468	'
Total Assets:	'	'	'
Total Assets	$447,581	'	$511,108

Segment_Reporting_Geographical4

Segment Reporting, Geographical Information (Details Textual)	3 Months Ended
	Mar. 31, 2014
	Segment
Segment Reporting, Geographical Information (Textual)	'
Number of business segments	2
Number of geographic segments	2

Equity_Details

Equity (Details) (USD $)

0 Months Ended

3 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

Aug. 14, 2007

Mar. 31, 2014

Feb. 24, 2014

Jan. 02, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Feb. 24, 2014

Mar. 31, 2014

Jan. 02, 2014

Feb. 24, 2014

Mar. 31, 2014

Mar. 31, 2014

Feb. 24, 2014

Mar. 31, 2014

Jan. 02, 2014

Feb. 24, 2014

Steven Girgenti [Member]

Dr Oscar Bronsther [Member]

Alvaro Pascual - Leone [Member]

Jason Barton [Member]

Jose Romano [Member]

Josef Zihl [Member]

Fountainhead Capital Partners Limited [Member]

Lowell Rush [Member]

Securities Offering [Member]

Consulting and Advisory Services [Member]

Consulting and Advisory Services [Member]

Consulting and Advisory Services [Member]

Consulting and Advisory Services [Member]

Consulting and Advisory Services [Member]

Consulting and Advisory Services [Member]

Common Stock [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series C Preferred Stock [Member]

Del Mar Consulting [Member]

Alex Partners, LLC [Member]

Garden State Securities, Inc (GSS)

J and M Group, Llc [Member]

Fountainhead [Member]

Fountainhead Capital Partners Limited [Member]

Fountainhead Capital Partners Limited [Member]

Placement Agent Agreement [Member]

Placement Agent Agreement [Member]

Fountainhead Capital Partners Limited [Member]

Fountainhead Capital Partners Limited [Member]

Equity (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate sale of closing comprised shares, value

'

'

'

'

'

'

'

'

'

'

'

'

'

$4,070,140

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock shares, Shares

'

2,261,214

420,838

792,523

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

210,419

1,130,621

396,262

'

'

'

210,419

1,130,621

396,262

'

Shares issued during period

'

'

'

'

'

'

'

'

'

'

'

792,523

'

'

'

'

'

'

'

'

'

1,130,621

'

'

'

324,805

2,062,108

1,130,621

'

'

'

'

Common Stock, par value (in dollars per share)

'

$0.00

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.80

'

'

'

'

'

$1.80

'

'

'

'

Warrants exercisable period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'3 years

'

'

'

'

Number of shares of common stock percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

50.00%

'

'

'

'

Warrant exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.8

2.05

'

'

'

'

'

3.08

'

'

'

'

Shares of series C convertible preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15.15

Aggregate investment amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

757,700

Conversion of stock, shares converted

107

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued value

'

'

'

'

'

5,000

5,000

1,563

1,563

1,563

1,420

'

2,222

'

'

5,400

3,600

66,000

4,700

15,000

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued shares

'

'

'

'

'

2,294

2,222

710

694

694

3,125

'

5,000

'

'

3,000

2,000

30,000

2,500

6,276

'

'

'

'

'

'

'

'

'

'

'

'

Shares under the original Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

ShareBased_Compensation_Detail

Share-Based Compensation (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Stock Warrants [Member]	'	'
Details of the outstanding rights, options and warrants and value of such rights, options and warrants	'	'
Options Outstanding, Beginning Balance	1,404,599	1,749,874
Number of shares, Granted	3,810,579	'
Number of shares, Exercised	'	-341,941
Number of shares, Cancelled or expired	-212,961	-3,334
Options Outstanding, Ending Balance	5,002,217	1,404,599
Weighted average exercise price per share, Outstanding, Beginning Balance	$3.39	$3.03
Weighted average exercise price per share, Granted	$2.52	'
Weighted average exercise price per share, Exercised	'	$1.49
Weighted average exercise price per share, Cancelled or expired	$4.50	$10.50
Weighted average exercise price per share, Outstanding, Ending balance	$2.68	$3.39
Stock options [Member]	'	'
Details of the outstanding rights, options and warrants and value of such rights, options and warrants	'	'
Options Outstanding, Beginning Balance	5,557	5,557
Number of shares, Granted	'	'
Number of shares, Exercised	'	'
Number of shares, Cancelled or expired	'	'
Options Outstanding, Ending Balance	5,557	5,557
Weighted average exercise price per share, Outstanding, Beginning Balance	$20.25	$20.25
Weighted average exercise price per share, Granted	'	'
Weighted average exercise price per share, Exercised	'	'
Weighted average exercise price per share, Cancelled or expired	'	'
Weighted average exercise price per share, Outstanding, Ending balance	$20.25	$20.25

ShareBased_Compensation_Detail1

Share-Based Compensation (Details 1) (Stock options [Member], USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Stock options [Member]	'	'
Options and warrants expensed	'	'
Risk-free interest rates	0.78%	'
Expected life	'3 years	'0 years
Expected dividends	0.00%	'
Expected volatility	75.00%	'
Vycor Common Stock fair value	$2.05	'

ShareBased_Compensation_Detail2

Share-Based Compensation (Details Textual) (USD $)

1 Months Ended

3 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

2 Months Ended

0 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

Jul. 31, 2013

Jul. 31, 2013

14-May-14

Mar. 31, 2014

Mar. 31, 2013

Feb. 24, 2014

Jan. 02, 2014

Sep. 30, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Nov. 30, 2013

Nov. 30, 2013

Jan. 02, 2014

Mar. 31, 2014

Mar. 31, 2014

Feb. 29, 2008

Feb. 29, 2008

31-May-10

Feb. 29, 2008

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Jan. 02, 2014

Jun. 02, 2013

Mar. 31, 2014

Stock options [Member]

Stock options [Member]

Stock Warrants [Member]

Stock Warrants [Member]

Del Mar Consulting [Member]

Alex Partners, LLC [Member]

Dr Donald O Rourke [Member]

Board of Directors Chairman [Member]

Scientific Advisory Board [Member]

Stock Option Plan [Member]

Stock Option Plan [Member]

Stock Option Plan [Member]

Stock Option Plan [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Consulting Agreement [Member]

Extension Agreement [Member]

Extension Agreement [Member]

Advisory Agreement [Member]

Advisory Agreement [Member]

Advisory Agreement [Member]

Stock Warrants [Member]

Chief Executive Officer [Member]

President [Member]

President [Member]

Common Stock [Member]

Steven Girgenti [Member]

Dr Oscar Bronsther [Member]

Alvaro Pascual - Leone [Member]

Jason Barton [Member]

Jose Romano [Member]

Josef Zihl [Member]

Lowell Rush [Member]

Del Mar Consulting [Member]

Alex Partners, LLC [Member]

J and M Group, LLC [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Subsequent Event [Member]

Share-Based Compensation (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ownership percentage of outstanding voting stock for the options to be granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'More than 10%.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of options granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Not less than 110% of the fair market value of the common stock on the grant date.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option expired period determined by the board of directors

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Not extend mare than 10 years from the grant date.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding voting stock expire from grant date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting period for employees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares, Granted

'

'

'

'

'

'

'

'

'

'

3,810,579

'

'

'

'

'

'

'

500,000

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of number of shares covered by plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price per share

'

'

'

'

'

'

'

'

'

'

$2.52

'

'

'

'

'

'

'

$0.14

'

$0.14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of options vested on first anniversary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33.33%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of options vested on second anniversary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33.33%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of options vested on third anniversary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33.33%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Grant expire date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12-Feb-18

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options cancelled or expired

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

166,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation expenses

'

'

'

$316,000

'

'

'

'

'

'

'

'

'

'

'

$36,250

$28,125

'

'

'

'

'

'

'

'

'

'

'

'

$78,620

'

'

'

$33,000

'

Weighted-average remaining contractual life of outstanding options

'

'

'

'

'

'

'

'

'3 years 10 months 17 days

'

'2 years 4 months 6 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation shares issued to nonemployees for services, share

'

'

'

'

'

'

'

'

'

'

'

'

33,000

27,000

'

'

'

'

'

'

'

'

2,294

2,222

710

694

694

1,420

2,222

'

3,000

2,000

6,276

'

2,500

Share-based compensation shares issued to nonemployees for services, value

'

'

'

33,000

168,655

'

'

'

'

'

'

'

66,000

54,000

'

'

'

'

'

'

'

7,813

5,000

5,000

1,563

1,563

1,563

3,125

5,000

'

5,400

3,600

15,000

'

4,700

consultancy agreement period

'

'

'

'

'

'

'

'

'

'

'

'

'3 months

'3 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total unrecognized compensation costs related to warrant and stock awards and non-vested options

'

'

'

'

'

'

'

175,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued during period, Restricted Stock, shares

30,000

15,000

45,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30,000

'

Stock Issued during period, Restricted Stock, value

66,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

66,000

'

Warrants issued to purchase common stock shares, Shares

'

'

'

2,261,214

'

420,838

792,523

'

'

'

'

'

'

'

7,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock shares, Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,522

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issue to purchase commmon stock of share at an exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.08

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Warrant Liability	$1,511,033	'
Level 1 [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Warrant Liability	'	'
Level 2 [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Warrant Liability	'	'
Level 3 [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Warrant Liability	$1,511,033	'

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 1) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
			Fair Value, Inputs, Level 3 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'
Balance at December 31, 2013	$1,511,033	'	'
Issuance of Series A Warrants and Placement Agent Warrants as part of Offering Units on January 2, January 31, February 24, February 28 and March 31, 2014	'	'	1,764,317
Change in fair value	'	'	-253,284
Balance at March 31, 2014	$1,511,033	'	$1,511,033

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details 2) (Warrant [Member], USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Warrant [Member]	'	'
Fair Value Assumptions [Abstract]	'	'
Risk-free interest rates, Minimum	0.68%	'
Risk-free interest rates, Maximum	0.93%	'
Expected life	'3 years	'0 years
Expected dividends	0.00%	'
Expected volatility, Minimum	71.00%	'
Expected volatility, Maximum	83.00%	'
Vycor Common Stock fair value minimum	$1.88	'
Vycor Common Stock fair value maximum	$2.39	'

Fair_Value_Measurements_Detail3

Fair Value Measurements (Details Textual) (Fair Value, Measurements, Recurring [Member])	3 Months Ended
	Mar. 31, 2014
Fair Value, Measurements, Recurring [Member]	'
Fair Value measurements (Textuals)	'
Issuance Of Series A Warrants And Placement Agent Warrants Shares	2,062,108

Commitments_and_Contingencies_

Commitments and Contingencies (Details)	1 Months Ended		3 Months Ended
	Jun. 30, 2012	Jun. 30, 2012	Mar. 31, 2014	Mar. 31, 2013
	USD ($)	EUR (€)	USD ($)	USD ($)
			sqft
Commitments and Contingencies (Textual)	'	'	'	'
Area of leased building (sq. ft)	'	'	10,000	'
Rent expenses plus sales tax (per month)	'	'	$14,260	'
Term of lease	'	'	'5 years 6 months	'
Lease expiration date	'	'	31-Jul-17	'
Approximate preliminary assessed trade tax	94,000	75,000	'	'
Rent expense	'	'	$50,178	$48,553

Consulting_and_Other_Agreement1

Consulting and Other Agreements (Details) (USD $)	1 Months Ended		3 Months Ended	0 Months Ended	1 Months Ended
	Jul. 31, 2013	Jul. 31, 2013	14-May-14	Jan. 02, 2014	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2013	Nov. 30, 2012
				Fountainhead [Member]	Del Mar Consulting [Member]	Del Mar Consulting [Member]	Alex Partners, LLC [Member]	Alex Partners, LLC [Member]
Consulting and Other Agreements (Textual)	'	'	'	'	'	'	'	'
Consulting agreement duration	'	'	'	'	'	'12 months	'	'12 months
Shares received under consulting agreement, value	'	'	'	'	$33,000	'	$27,000	'
Cash payment pursuant to consulting agreement	'	'	'	'	66,000	'	54,000	'
Maximum cash payment for consulting services (monthly)	'	'	'	10,000	'	'	'	'
Minimum cash payment for consulting services	'	'	'	$5,000	'	'	'	'
Stock issued during period, Restricted Stock, shares	30,000	15,000	45,000	'	'	'	'	'
Description of agreement	'(i) 90 days from the date of execution of the Agreement or (ii) the end of the offering period of any securities financing undertaken by the Company in connection with the Placement Agent Agreement.	'	'	'	'	'	'	'

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)

Mar. 31, 2014

Dec. 31, 2013

Jan. 02, 2014

Mar. 31, 2014

Jan. 02, 2014

Jan. 02, 2014

Aug. 31, 2013

Mar. 31, 2014

Oct. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Consulting Agreement [Member]

Consulting Agreement [Member]

Employment Agreements [Member]

Conversion Agreement [Member]

Subsequent Event [Member]

Fountainhead [Member]

Fountainhead [Member]

Peter Zachariou [Member]

David Cantor [Member]

Fountainhead and Peter Zachariou [Member]

Secured Loan One [Member]

Subsequent Event [Member]

Related Party Transactions (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

Loan amount

'

$2,373,556

'

'

'

'

$10,000

'

$35,000

'

'

$2,247,037

Extension of maturity date

'

'

'Fountainhead amended their Consulting Agreement to extend the term of the Consulting Agreement to to January 2, 2015.

'

'

'

'

'

'

'

'

'

Loan repayment term

'

'

'

'

'

'

'

'

'

'

'

'Fountainhead and Peter Zachariou agreed to extend the maturity of all of the Company's debt obligations due to them due to as of August 9, 2013 (aggregating $2,247,037) to January 2, 2017, subject to the earlier repayment of such debt upon the occurrence of certain specified conditions.

Repayment of debt

'

'

'

'

'

'

'

91,519

'

20,000

15,000

'

Annual compensation of employment agreements

'

'

'

'

110,000

'

'

'

'

'

'

'

Description of employment agreements

'

'

'

'

'The aforementioned Employment Agreements provide for annual compensation of $110,000, payment of which is deferred for 12 months from the Effective Date and is subject to the achievement of certain enumerated milestone conditions.

'

'

'

'

'

'

'

Decrease in retainer payable to Fountainhead

'

'

10,000

'

'

'

'

'

'

'

'

'

Retainer payable to Fountainhead

'

'

5,000

'

'

'

'

'

'

'

'

'

Accrued consulting fee

'

'

'

'

'

1,426,542

'

'

'

'

'

'

Common Stock issued to Fountainhead

$1,028

$675

'

$15,000

'

'

'

'

'

'

'

'

Common Stock issued to Fountainhead, Shares

10,285,832

6,757,225

'

6,276

'

'

'

'

'

'

'

'

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (USD $)	3 Months Ended		1 Months Ended		2 Months Ended	1 Months Ended	2 Months Ended
	Mar. 31, 2014	Mar. 31, 2014	Apr. 25, 2014	Apr. 25, 2014	31-May-14	Apr. 25, 2014	31-May-14	31-May-14	31-May-14
	Series A Warrants [Member]	Series B Warrants [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
				Series A Warrants [Member]	Series A Warrants [Member]	Series B Warrants [Member]	Steven Girgenti [Member]	Alvaro Pasual Leone [Member]	Josef Zihl [Member]
							Common Stock [Member]	Common Stock [Member]	Common Stock [Member]
Subsequent Events (Textual)	'	'	'	'	'	'	'	'	'
Common stock issued in consideration for services	'	'	'	'	'	'	$5,000	$1,563	$3,125
Common stock issued in consideration for services, Shares	'	'	'	258,298	'	258,298	2,222	727	1,453
Common stock shares issued	1,130,621	1,130,621	516,594	'	'	'	'	'	'
Sale of additional units at final close offering	'	'	929,860	'	'	'	'	'	'
Offering Agreements and removal of anti-dilution, Description	'	'	'	'	'The investors agreed to waive their anti-dilution rights (which arose in the event the Company sold securities at a price below $2.05 within one year of the date that the initial Registration Statement has been declared effective by the SEC) in consideration of the Company's agreement not to sell any securities at a price below $2.05 within such one-year period. The Waivers become effective as to all the Common Stock issued in the offering once the Company receives the agreement of the holders of eighty percent (80%) of the Common Stock issued in the offering and the holders of eighty percent (80%) of the Common Stock issued in each closing. As of May 14, 2014, the Company had received waivers from the holders of 93.9 percent of the shares issued in the offering, and over 80 percent for each closing, and so the Waivers have been declared effective on 100 percent of the Common Stock issued in the Offering.	'	'	'	'
Private placement offering	'	'	'	'	$5,000,000	'	'	'	'